CXCR4 high-expression type iPSC-NK cell capable of enhancing bone marrow and tumor tissue homing ability, and preparation method and application of CXCR4 high-expression type iPSC-NK cell
By integrating the CXCR4 and membrane-bound IL-15/IL-15RA fusion protein genes into iPSCs, iPSC-NK cells with high CXCR4 expression were constructed, solving the problems of homing and survival of NK cells in tumor therapy. This achieved broad-spectrum anti-tumor effects in hematologic and solid tumors, and is GMP-compliant in production with low toxicity, making it suitable for large-scale allogeneic applications.
Patent Information
- Application Number
- CN202610591005.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-30
- Publication Date
- 2026-05-29
AI Technical Summary
Existing iPSC-derived NK cells have limitations in tumor treatment due to insufficient homing ability, limited in vivo survival, insufficient penetration into solid tumors, and difficulties in GMP-compliant production, which restrict their widespread application in hematologic malignancies and solid tumors.
By integrating the CXCR4 and membrane-bound IL-15/IL-15RA fusion protein genes into iPSCs using CRISPR/Cas9 gene editing technology, iPSC-NK cells with high CXCR4 expression were constructed, enhancing their homing ability in bone marrow and tumor tissues, and improving the in vivo survival and expansion capacity of NK cells through autocrine/paracrine activation loops.
It significantly improves the homing efficiency and in vivo survival of NK cells in tumor tissues, enhances their killing activity against solid tumors with high CXCL12 expression, achieves broad-spectrum anti-tumor effects in hematologic malignancies and solid tumors, and has GMP-compliant production and low toxicity, making it suitable for large-scale allogeneic applications.